Item 8.01 Other Events.
On April 7, 2023, the board of directors (the "Board") of Eucrates Biomedical
Acquisition Corp. (the "Company") approved the redemption of all of the
outstanding ordinary shares of the Company, no par value, that were included in
the Company's initial public offering (the "Public Shares"). The Company
anticipates that it will not be able to consummate an initial business
combination within the time period required by its Amended and Restated
Memorandum and Articles of Association, and as a result the Company intends to
dissolve and liquidate. The redemption of the Public Shares is expected to be
completed on April 27, 2023. As of the close of business on April 26, 2023, the
Company will stop trading its Public Shares, and each Public Share held at that
time will represent the right to receive the redemption amount of approximately
$10.00.
On April 11, 2023, the Company issued a press release announcing the foregoing.
A copy of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
Exhibit Description
99.1 Press Release, dated April 11, 2023
104 Cover Page Interactive Data File (formatted as Inline XBRL document).
© Edgar Online, source Glimpses